Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Creative Medical Technology Holdings (CELZ) EBITDA (2016 - 2025)

Historic EBITDA for Creative Medical Technology Holdings (CELZ) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Creative Medical Technology Holdings' EBITDA fell 1472.14% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 804.27%. This contributed to the annual value of -$5.7 million for FY2024, which is 220.15% down from last year.
  • Latest data reveals that Creative Medical Technology Holdings reported EBITDA of -$1.3 million as of Q3 2025, which was down 1472.14% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Creative Medical Technology Holdings' EBITDA registered a high of -$303944.0 during Q1 2021, and its lowest value of -$6.3 million during Q4 2022.
  • Moreover, its 5-year median value for EBITDA was -$1.3 million (2025), whereas its average is -$1.5 million.
  • As far as peak fluctuations go, Creative Medical Technology Holdings' EBITDA tumbled by 35586.23% in 2021, and later soared by 7177.67% in 2023.
  • Quarter analysis of 5 years shows Creative Medical Technology Holdings' EBITDA stood at -$1.5 million in 2021, then tumbled by 326.28% to -$6.3 million in 2022, then surged by 71.78% to -$1.8 million in 2023, then fell by 6.43% to -$1.9 million in 2024, then skyrocketed by 32.49% to -$1.3 million in 2025.
  • Its EBITDA stands at -$1.3 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$1.7 million for Q1 2025.